Exchange: NYSE·Updated 07:57 PM EST

TAK News

News
all
press releases
Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Time to Buy?
Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy...
MarketBeat
Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Time to Buy?
Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy...
MarketBeat
More News
Takeda (TSE:4502/NYSE:TAK) announced that ORZEYFUL (oveporexton) CIV is now available in the U.S. by prescription for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults, bringing the first and only orexin agonist to this community. Learn more at ORZEYFUL.com. This press...
Business Wire
ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.
Zacks
Revealing a significant insider sell on November 5, Giles Platford, President at Takeda Pharmaceutical Co (NYSE:TAK), as per the latest SEC filing. What Happened: After conducting a thorough analysis, Platford soldread more...
Benzinga
Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
Zacks
Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
Zacks
Takeda Pharmaceutical Co (NYSE:TAK) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of...
Business Wire
Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA...
Business Wire
Healthcare stocks are heating up, and investors have a fresh lineup of catalysts to watch. Pfizer (NYSE:PFE) is pushing its oncology story back into the spotlight, while NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a high-volatility biotech to watch as brain-cancer milestones, Abu Dhabi expansion and a battle around key technical levels converge. Avantor (NYSE:AVTR) faces a crucial earnings test that could determine whether its recovery has more room to run, while Eli Lilly and Co (NYSE:LLY) is building on its blockbuster drug franchise with encouraging new pediatric clinical data. Takeda Pharmaceutical (NYSE:TAK) brings global pipeline potential and diversified drug-market exposure to the mix, while MoonLake Immunotherapeutics (NASDAQ:MLTX) is drawing trader attention with active trading putting its next potential catalyst under the microscope.
24-7 Market News

Advertisement|Remove ads.